title: Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban.
abstract: Prevention of deep vein thrombosis (DVT) is important in patients undergoing major orthopedic surgery. Although the detection of an elevated D-dimer level is useful for predicting DVT, it is not efficacious in postoperative patients being treated with anti-Xa agents. The soluble platelet glycoprotein VI (sGPVI) level is a marker of activated platelets, but not bleeding. Therefore, sGPVI levels are usually examined as a predictor of DVT in such patients. In the present study, 83 orthopedic patients were treated with 30 mg of edoxaban for prophylaxis of DVT. Fourteen patients developed DVT and 17 patients discontinued the prophylaxis due to decreased hemoglobin levels. Plasma levels of sGPVI in the patients were significantly higher after surgery than before surgery. On day 1, the sGPVI levels increased, while the platelet counts decreased. There were no significant differences in D-dimer, soluble fibrin, or FDP levels in orthopedic patients with and without DVT before surgery and on days 1, 4, and 8. Plasma sGPVI levels were significantly higher in the patients with DVT than in those without DVT on days 1 and 4. Plasma levels of D-dimer were significantly higher in patients with withdrawal than in those without. However, there were no significant differences in sGPVI levels between those with and without withdrawal. As D-dimer levels are known to increase in patients with withdrawal, this parameter is not useful for evaluating the risk of DVT in these patients. In contrast, the sGPVI level is not increased in those with withdrawal and may therefore be useful for evaluating the risk of DVT in postoperative patients treated with an anticoagulant.
authors.affiliation: Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Takumi
authors.initials: T
authors.lastname: Aota
authors.forename: Katsuki
authors.initials: K
authors.lastname: Naitoh
authors.forename: Hideo
authors.initials: H
authors.lastname: Wada
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Noriki
authors.initials: N
authors.lastname: Miyamoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Wakabayashi
authors.forename: Kakunoshin
authors.initials: K
authors.lastname: Yoshida
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Asanuma
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Kohshi
authors.initials: K
authors.lastname: Ohishi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shimokariya
authors.forename: Norikazu
authors.initials: N
authors.lastname: Yamada
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Nishikawa
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Katayama
authors.forename: Atsumasa
authors.initials: A
authors.lastname: Uchida
authors.forename: Akihiro
authors.initials: A
authors.lastname: Sudo
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D065427:Factor Xa Inhibitors / Q000627:therapeutic use; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures / Q000009:adverse effects; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism*; D011183:Postoperative Complications / Q000097:blood*; D011725:Pyridines / Q000627:therapeutic use*; D012307:Risk Factors; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000097:blood*
chemical_list: D015415:Biomarkers; D065427:Factor Xa Inhibitors; D005338:Fibrin Fibrinogen Degradation Products; D010980:Platelet Membrane Glycoproteins; D011725:Pyridines; D013844:Thiazoles; C036309:fibrin fragment D; C098341:platelet membrane glycoprotein VI; C552171:edoxaban